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Androgen deficiency is a pervasive problem in the older male population and is thought to be
responsible for many symptoms once considered to be the result of normal aging. Numerous
methods have been proposed to facilitate the detection of men at risk for androgen deficiency. In
this article, we propose a novel screening tool, the quantitative Androgen Deficiency in the Aging
Male (qADAM) questionnaire and report its successful use in quantifying the severity of androgen
deficiency in a group of older men. Fifty-seven males scheduled to undergo radical prostatectomy
for prostate cancer completed the qADAM as well as the Sexual Health Inventory for Men (SHIM)
and the Expanded Prostate Cancer Index Composite hormonal/sexual (EPICh/EPICs) questionnaires.
Thirty-four men also had serum testosterone levels measured for comparison. The qADAM showed
statistically significant correlation to the SHIM (P¼0.001), EPICh (P¼0.016), EPICs (P¼o0.001),
and serum testosterone (P¼0.046). The qADAM represents a viable alternative to existing
questionnaires used to detect androgen deficiency and to assess response to treatment.
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Introduction
Androgen deficiency is a serious problem in the
older male population, thought to affect approxi-
mately 1 in 200 men.
1 Although the precise extent to
which this process occurs is controversial, the
largest study conducted thus far involved 3220
European men and showed a decline in testosterone
and free testosterone levels by 0.4 and 1.3% per
year, respectively.
2 The common symptoms of this
decline in androgens have not been fully defined, as
have those secondary to declining estrogen levels in
women. Some symptoms that were earlier thought to
be the effects of aging in males have been found to
be more prevalent in patients with hypogonadism.
3
These include changes in bone mineral density,
3–6
muscle strength,
7–9 cognition,
10 body composi-
tion,
11,12 and sexual function.
13–15 These studies
provide evidence of a correlation between decreas-
ing testosterone levels and symptoms, although they
fail to give clear evidence for causality.
The Saint Louis University Androgen Deficiency
in the Aging Male (ADAM) questionnaire developed
by Morley et al.
16 has been widely used as a
screening tool for detecting men at risk for androgen
deficiency since its development in 2000. It was
shown to have a sensitivity of 88%, emphasizing its
utility as a screening test. It was shown to be less
specific, however, at 60%. A recent study by
Martı ´nez-Jabaloyas et al.
17 in Spain showed a lower
sensitivity and specificity than earlier estimated, at
84 and 36.6%, respectively, in 230 patients over age
50. These results point to the need to modify the
ADAM questionnaire in order to better facilitate the
early diagnosis of patients with hypogonadism.
The standard ADAM questionnaire consists of 10
‘yes or no’ questions concerning symptoms of andro-
gen deficiency. See Figure 1.
16 These ‘yes’ or ‘no’
questions, though effective at identifying symptoms
associated with androgen deficiency, offer no infor-
mation about the severity of symptoms. Thus, there is
no simple and non-invasive way to monitor the
response to treatment using this tool alone, unless
symptoms completely resolve. We propose a variant
of the ADAM questionnaire using a graded response,
which we call the quantitative ADAM questionnaire,
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naire will allow practitioners to more accurately
screen for earlier unrecognized androgen deficiency,
as well as monitor patients’ responses to treatment.
Materials and methods
Male patients who were scheduled to undergo a
radical prostatectomy for prostate cancer and who
had not undergone neoadjuvant hormonal therapy
were eligible for this study. Institutional review
board approval was obtained. Each patient was
asked to complete the qADAM questionnaire pre-
operatively, as well as the Sexual Health Inventory
for Men (SHIM) and the Expanded Prostate Cancer
Index Composite hormonal and sexual domains
(EPIC, EPICh, EPICs).
18,19 Patients were encouraged
to fill out the questionnaires as honestly as possible,
and to fill them out completely. All incomplete
surveys were excluded from the study. Patients were
asked to have serum testosterone levels drawn for
comparison.
qADAM questionnaire
The qADAM questionnaire consisted the 10 ques-
tions of the original ADAM, with ‘yes’ and ‘no’
replaced by a Likert scale of 1–5, in which 5
represented the absence of a given symptom and 1
represented maximal symptoms.
20 All questions
were weighted equally. The summation of these
responses yielded a total qADAM score between 10
and 50, with 10 being most symptomatic and 50
being least symptomatic.
Serum testosterone
Testosterone measurements were performed using
the Beckman Access II platform assay (Beckman
Coulter, Fullterton, CA, USA). Only testosterone
levels that were drawn on the day that the
questionnaires were completed were used in our
analysis. Testosterone levels were drawn at random
times during the day between 9 AM and 5 PM.
Results
A total of 57 patients completed the qADAM
questionnaire. The mean age of the patients studied
was 62±10.9 years. The results of the question-
naires were compared using one-way analysis of
variance for repeated measurements.
qADAM and serum testosterone
Of the 57 patients that completed the qADAM
questionnaire, 34 (60%) consented to have serum
testosterone values measured for analysis. Eleven of
these patients were hypogonadal, defined as having
serum testosterone values p300ngml
 1.T h eq A D A M
questionnaire positively correlated with the serum
Questions Used as Part of the Saint Louis University ADAM
Questionnaire
1. Do you have a decrease in libido (sex drive)?
2. Do you have a lack of energy?
3. Do you have a decrease in strength and/or endurance?
4. Have you lost height?
5. Have you noticed a decreased ‘‘enjoyment of life’’?
6. Are you sad and/or grumpy?
7. Are your erections less strong?
8. Have you noted a recent deterioration in your ability to play
sports?
9. Are you falling asleep after dinner?
10. Has there been a recent deterioration in your work performance?
NOTE. A positive questionnaire result is defined as a ‘‘yes’’ answer to
questions 1 or 7 or any 3 other questions.
Figure 1 The Saint Louis University ADAM questionnaire.
Questions Used as Part of the qADAM Questionnaire
1. How would you rate your libido (sex drive)?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
2. How would you rate your energy level?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
3. How would you rate your strength/endurance?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
4. How would you rate your enjoyment of life?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
5. How would you rate your happiness level?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
6. How strong are your erections? 
   (1= extremely weak 5= extremely strong)
    1   2   3   4   5
7. How would you rate your work performance over the past 4 weeks?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
8. How often do you fall asleep after dinner?
 1(never) 2(1-2/week) 3(3-4/week) 4(5-6/week) 5(every night)
9. How would you rate your sports ability over the past 4 weeks?
  1(terrible) 2(poor) 3(average) 4(good) 5(excellent)
10. How much height have you lost?
 1(2” or more) 2(1.5-1.9”) 3(1-1.4”) 4(0.5-0.9”) 5(none-0.4”)
Figure 2 The quantitative ADAM questionnaire.
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2¼0.119,
P¼0.046, and an F-score of 4.311. See Graph 1.
qADAM and EPIC
All of the patients in the study group had EPIC
scores available for both the sexual (EPICs) and
hormonal (EPICh) domains. There was a strong
positive correlation between qADAM scores and
the EPICs with r¼0.571, r
2¼0.326, and a P-value of
o0.001. The F-value was 26.6. See Graph 2. The
EPICh also showed a positive correlation with the
qADAM questionnaire, with r¼0.0314, r
2¼0.101,
P¼0.016, and F¼6.173. See Graph 3.
qADAM and SHIM
Fifty-three patients (93%) completed both the
qADAM and the SHIM. The qADAM scores showed
a strongly positive correlation with the SHIM
questionnaire. A linear regression showed
r¼0.438, r
2¼0.192, F¼12.14, and P¼0.001. See
Graph 4.
Discussion
Although it is estimated that 40% of men over the
age of 45 have low testosterone, our current screen-
ing tools lack the specificity to identify most of
these patients. Often many of the symptoms of
hypogonadism are subtle, with an insidious onset.
Consequently, improved surveillance and imple-
mentation of routine screening of ‘‘at-risk’’ males
could conceivably benefit otherwise unrecognized
patients.
Currently, one of the most widely used screening
tools is the Saint Louis University ADAM question-
naire. This questionnaire does not allow for the
quantification of responses. As a result, it is difficult
for clinicians to assess the degree of improvement in
symptoms after initiating therapy. Heinemann, et al.
21
have proposed another test, the Aging Male Symptom
(AMS) rating, a battery of 17 questions graded on a
Likert Scale of 1–5. Unlike the ADAM questionnaire,
the AMS questionnaire allows one to quantify the
degree of improvement in hypogonadal symptoms
after initiating therapy. However, like the ADAM
questionnaire, the AMS lacks specificity. Moore
et al.
22 conducted a study of 1174 androgen deficient
males being treated with testosterone and used the
AMS to assess response to treatment. The authors
found a sensitivity of 96% but a specificity of only
30%. Additionally, some authors have criticized the
AMS as excessively long and cumbersome, making its
practical application difficult.
23
We believe that the qADAM is a viable alternative
to screening tools such as the ADAM and the AMS.
The qADAM correlates with serum testosterone,
indicating that it has potential as a screening as
well as a diagnostic tool. Furthermore, the
qADAM correlated with other instruments of sexual
and hormonal function, such as the sexual and
hormonal domains of the EPIC and the SHIM
questionnaires.
qADAM vs. Serum Testosterone (ng/dL)
0
100
200
300
400
500
600
700
800
900
qADAM score
S
e
r
u
m
 
T
e
s
t
o
s
t
e
r
o
n
e
 
(
n
g
/
d
L
)
r= 0.345
r2= 0.119
p= 0.046
F score= 4.311
10 50 45 40 35 30 25 20 15
Graph 1 Serum testosterone levels versus the qADAM score.
EPICs vs. qADAM
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Graph 2 The EPIC sexual domain score versus the qADAM
score.
qADAM vs. EPICh
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Graph 3 The EPIC hormonal domain score versus the qADAM
score.
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serve further elaboration. We chose an experimental
group composed of 57 men with prostate cancer
scheduled to undergo radical prostatectomy. We
acknowledge that the diagnosis of prostate cancer
may have had an impact on these patients’ symp-
toms of hypogonadism and their qADAM responses.
Additionally, our decision to measure testosterone
levels over the course of the day may draw
some scrutiny. It is known that younger males often
show variability in their testosterone level over the
course of the day. It is believed by some authors,
however, that the diurnal variability in testosterone
levels seen in younger males is absent in older
males.
24 Given that our sample was composed
entirely of men older than age 50, we did not feel
that the variability in collection times altered
the data significantly. Furthermore, we realize that
the data presented do not validate the qADAM, but
simply show significant correlations with serum
testosterone and responses to other questionnaires,
such as the ADAM, the SHIM, and the EPIC
questionnaires.
Although these initial results have been promis-
ing, some aspects of the qADAM should be explored
more thoroughly. In particular, future study will be
conducted to evaluate the ability of the qADAM
to monitor response to treatment over time. Further
work to define the sensitivity and specificity of
the qADAM using a larger group of patients will
also be needed.
Conclusions
The qADAM questionnaire offers a useful alterna-
tive to existing tools for screening and assessing
hypogonadism. Unlike most other commonly used
questionnaires, it provides results that may be
quantified and, thus, more easily followed over
time. We have shown that the qADAM correlates
well with several existing screening tools, as well as
with serum testosterone levels. In light of these
results, we believe that the qADAM may be
implemented safely and effectively.
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